Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11649279 Anti-complement factor C1Q antibodies and uses thereof

Patent 11649279 was granted and assigned to Annexon, Inc. on May, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

116492790

Patent Inventor Names

Michael Leviten0

Arnon Rosenthal0

Date of Patent

May 16, 2023

Patent Application Number

171728070

Date Filed

February 10, 2021

Patent Citations

‌

US Patent 10927167 Anti-complement factor C1Q antibodies and uses thereof

‌

US Patent 10723788 Anti-complement factor C1q Fab fragments and uses thereof

‌

US Patent 10227398 Anti-complement factor C1q antibodies and uses thereof

‌

US Patent 10240156 Modulation of synaptic maintenance

‌

US Patent 10316081 Humanized anti-complement factor C1Q antibodies

‌

US Patent 10330671 Modulation of synaptic maintenance

‌

US Patent 10590190 Anti-complement factor C1q antibodies and uses thereof

Patent Primary Examiner

‌

Aurora M Fontainhas

The present invention provides anti-C1q antibodies and methods of using the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11649279 Anti-complement factor C1Q antibodies and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API